Project UpdateJul 14, 2026, 08:32 AM
Conexeu Completes Preclinical Study for CXU™ Aesthetics Platform; Targets 2027 510(k)
AI Summary
Conexeu Sciences Inc. announced the completion of its 12-month P.R.O.O.F. preclinical study for its CXU™ tissue-restoration platform, positioning it for the large-volume body contouring market. The company aims to create a new 'bioregeneration' category, addressing a significant unmet need in medical aesthetics, including tissue changes following GLP-1 weight loss. Conexeu plans to submit a 510(k) application for its lead candidate in Q1 2027, leveraging a market projected to reach billions by 2030.
Key Highlights
- Completed 12-month P.R.O.O.F. preclinical study for CXU™ tissue-restoration platform.
- CXU™ aims to establish a new 'bioregeneration' category in large-volume injectable aesthetics.
- Buttock augmentation market projected to grow from $2.99B (2023) to $11.72B by 2030.
- Breast implant and reconstruction markets projected to approach $6B by 2030.
- GLP-1 related aesthetic provider revenue projected to grow from $0.7B to $2.0B by 2030.
- CXU™ is a thermosensitive, flowable collagen ECM scaffold designed for tissue regeneration.
- Company plans a 510(k) submission for its lead candidate in the first quarter of 2027.
Price Impact
More from CNXU